FXEMPIRE
All
Ad
Corona Virus
Stay Safe, FollowGuidance
World
101,072,802Confirmed
2,174,392Deaths
73,039,753Recovered
Fetching Location Data…
Advertisement
Advertisement
James Hyerczyk
Asia Pacific Shares

The major Asia Pacific stock indexes finished mostly higher on Thursday with China’s Shanghai Index losing ground in reaction to the news that Chinese regulators will probe tech-giant Alibaba for suspected monopolistic behavior.

According to reports, China’s State Administration for Market Regulation said through official online channels it has opened an investigation into Alibaba over monopolistic practices. The news was first reported by Bloomberg, and was announced by Chinese state news agency Xinhua.

Elsewhere, South Korea shares hit a record high in its longest rally since mid-2017. Japan shares edged near a 30-year high on recovery hopes and heavy machinery stocks’ gains. Australia shares rose on strong gains in the energy sector.

In the cash market on Thursday, Japan’s Nikkei 225 Index settled at 26668.35, up 143.56 or +0.54%. Hong Kong’s Hang Seng Index finished at 26386.56, up 43.46 or +0.16 and South Korea’s KOSPI Index closed at 2806.86, up 47.04 or +1.70%.

In China, the Shanghai Index settled at 3363.11, down 19.21 or -0.57% and in Australia, the S&P/ASX 200 Index finished at 6664.80, up 21.70 or +0.33%.

China Stocks Dip as Anti-Trust Probe into Alibaba Hits Tech Shares

China stocks inched lower on Thursday, dragged by tech shares after Beijing launched an anti-trust probe into Jack Ma’s Alibaba Group. The probe is part of an accelerating crackdown on monopolistic behavior in China’s booming internet space, and the latest setback for Alibaba founder Jack Ma.

Additionally, investor confidence in the tech sector was hit by news that China launched an antitrust investigation into Alibaba’s e-commerce and fintech empire.

Spooked investors dumped shares of Alibaba’s subsidiaries and affiliates, as well as other internet firms that risk being targeted by Chinese anti-trust regulators.

Advertisement

South Korea Leads Pre-Christmas Gains Across Asia

South Korean shares hit a record high on Thursday, leading gains for most emerging Asian stock markets in holiday-thinned trading after the country secured deals to import COVID-19 vaccines.

The deals with Pfizer Inc and Johnson & Johnson’s Janssen fueled a nearly 2% rise in Seoul’s KOSPI, adding an eighth straight week of gains, while the won firmed half a percent. South Korean officials signed the deals to import coronavirus vaccines to cover up to 16 million people, as it grapples with the third wave of infections.

Samsung Electronics shares soared 5.3%, after jumping as much as 6.6% to hit a record high earlier in the session. The KOSPI has risen 27.72% so far this year, gaining 11.0% in the previous 30 trading sessions.

Nikkei Edges Near 30-Year High on Recovery Hopes, Heavy Machinery Stocks’ Gains

Japanese shares inched up on Thursday to come within sight of a near three-decade high, as vaccine rollouts buoyed hopes of an economic recovery from the COVID-19 pandemic and heavy machinery stocks gained on a policy shift to greener energy.

Rollouts of COVID-19 vaccines are propping up hopes that the economic recovery can gain momentum next year, despite the headwinds from a recently-found more infectious strain and a delay in U.S. pandemic relief package.

Heavy machinery firms gained after Nikkei newspaper reported Japan’s new zero emission strategy would target a massive increase in offshore wind power.

For a look at all of today’s economic events, check out our economic calendar.
Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
IMPORTANT DISCLAIMERS
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
RISK DISCLAIMER
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.
FOLLOW US